Charlotte H. Ahern

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

Yaël P. Mossé, Megan S. Lim, Stephan D. Voss et al. · The Lancet Oncology · 2013 · 701 citations · Full text

Medicine, Oncology, Pediatrics +11

Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

Suman Malempati, Brenda J. Weigel, Ashish M. Ingle et al. · Journal of Clinical Oncology · 2011 · 178 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report

Julia Glade Bender, Alice Lee, Joel M. Reid et al. · Journal of Clinical Oncology · 2013 · 164 citations · Full text

Pharmacy, Oncology, Pharmacology +17

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

Mignon L. Loh, Sarah K. Tasian, Karen R. Rabin et al. · Pediatric Blood & Cancer · 2015 · 127 citations

Medicine, Oncology, Pharmacology +17

Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study

Yaël P. Mossé, Emily Lipsitz, Elizabeth Fox et al. · Clinical Cancer Research · 2012 · 122 citations · Full text

Medicine, Oncology, Pharmacology +17